Observational studyJournal of medical virology2019
Respiratory syncytial virus-associated illness in adults with advanced chronic obstructive pulmonary disease and/or congestive heart failure.
Observational study in Journal of medical virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06286007 (Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control), which is not on this map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis.The Journal of infectious diseases · 2023Pooled it
- The burden of respiratory syncytial virus in adults: a systematic review and meta-analysis.Epidemiology and infection · 2020Pooled it
- Respiratory Syncytial Virus Hospitalizations in Adults ≥50 Years of Age and Those With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations, 2018-2020.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Observational
- Efficacy and effectiveness of long-acting monoclonal antibodies and vaccines against RSV: a systematic review and meta-analysis of studies from 2018 to 2025.EClinicalMedicine · 2026Article
- Outpatient RSV Testing Rates Among US Adults with Lower Respiratory Tract Disease, 2017-2024.Infectious diseases and therapy · 2026Article
- Respiratory syncytial virus - from discovery to vaccines.Journal of medical microbiology · 2026Review
- Respiratory syncytial virus is associated with a higher disease burden than influenza and SARS-CoV-2 in adults with chronic lung disease: a multi-center cohort study.Respiratory research · 2026Article
- Unlocking the value of RSV vaccination in Japan: a return on investment analysis using an integrated actuarial-macroeconomic model.Frontiers in public health · 2026Article
- Respiratory viral infections in hospitalized adults: a comparative clinico-laboratory study of RSV, HMPV, and influenza.Virology journal · 2025Article
- Respiratory Syncytial Virus (RSV) as a Secondary Diagnosis among Hospitalized Patients in Germany: Outcomes and Economic Burden.Infectious diseases and therapy · 2025Article
- Disease Burden of RSV Infection in Adult Patients in Comparison to Influenza Virus Infection.Journal of medical virology · 2025Article
- Relationship Between Frailty and Respiratory Syncytial Virus Infection in Hospitalized Older Adults.Open forum infectious diseases · 2025Article
- Clinical features and survival analysis of adult patients with severe lower respiratory tract infection positive for respiratory syncytial virus.BMC pulmonary medicine · 2025Article
- Article
- Prevalence of Respiratory Syncytial Virus Infection in Hospitalized COPD Patients in Spain Between 2018-2022.Diseases (Basel, Switzerland) · 2025Article
- Burden of respiratory syncytial virus in older adults in Brazil: insights from national surveillance data for the 2022-2023 period.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025Article
- Correlation analysis between the severity of respiratory syncytial virus pneumonia and the expression levels of inflammatory cytokines in bronchoalveolar lavage fluid among infants and young children.Frontiers in pediatrics · 2025Article
- Relative Contribution of Diagnostic Testing to the Diagnosis of Respiratory Syncytial Virus in Hospitalized Adults in the United States.The Journal of infectious diseases · 2024Article
- Incidence of RSV in Adults: A Comprehensive Review of Observational Studies and Critical Gaps in Information.The Journal of infectious diseases · 2024Review
- Hospitalization Following Outpatient Diagnosis of Respiratory Syncytial Virus in Adults.JAMA network open · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) is recognized as a serious pathogen in people with chronic cardiopulmonary conditions. Immunoprophylaxis might be considered for adults at high-risk for frequent and severe RSV infection. Thus, we studied the incidence of RSV-related medically attended acute respiratory illness (MARI) in adults with severe chronic obstructive pulmonary disease (COPD) and/or congestive heart failure (CHF).
methodsSubjects ≥50 years of age with Gold Class III/IV COPD and/or American Heart Association class III/IV CHF and exposure to children ≥once per month were recruited. Subjects were evaluated over 1.5 to 2.5 years for RSV-associated MARI, defined as polymerase chain reaction (PCR) and/or seroresponse.
resultsFour hundred forty-five subjects were enrolled between October 2011 and May 2012. Overall, 99 RSV infections were documented by PCR or serology for a cumulative incidence of 22.2%. Of these, 42 (9.4%) subjects had protocol-specified RSV-MARI for an incidence of 4.68/100 patient-seasons. All-cause MARI was common (63.85/100 patient-seasons) with rhinovirus most commonly identified.
conclusionRSV infection was common in adults with severe COPD and/or advanced CHF. Given the severity of underlying cardiopulmonary diseases in the study population, most illnesses were surprisingly mild. Thus, active immunization rather than passive immunoprophylaxis with monoclonal antibodies may be a more cost-effective strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.